Skip to content

Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease.

Research output: Contribution to journalArticle

Standard

Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease. / Hezzell, Melanie; Block, Chloe; Laughlin, Danielle; Oyama, Mark A.

In: Journal of Veterinary Internal Medicine, Vol. 32, No. 5, 14.09.2018, p. 1509-1516.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Hezzell, Melanie ; Block, Chloe ; Laughlin, Danielle ; Oyama, Mark A. / Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease. In: Journal of Veterinary Internal Medicine. 2018 ; Vol. 32, No. 5. pp. 1509-1516.

Bibtex

@article{48bcb91db5c345a183452e76f0b326ed,
title = "Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease.",
abstract = "Background: Therapy targeted to achieve reduction in N-terminal pro-B-type natriuretic peptide (NT-proBNP) improves outcomes in human congestive heart failure (CHF) patients. Hypothesis: A pre-specified therapeutic algorithm that increased diuretic or pimobendan usage will reduce plasma NT-proBNP concentrations in dogs with CHF secondary to myxomatous mitral valve disease (MMVD). Animals: Twenty-six dogs with clinically stable CHF secondary to MMVD. Methods: Prospective, controlled before-and-after study. Dogs were examined up to 3 times over 21 days. Treatment was prescribed based on NT-proBNP as follows: <1500 pmol/L at baseline, no therapy adjustment at any point during the study (group 1); ≥1500 pmol/L and creatinine ≤3.0 mg/dL at baseline or subsequent visits, therapy escalated according to the algorithm (group 2); ≥1500 pmol/L at baseline, no therapy adjustment (group 3). Results: NT-proBNP decreased significantly in group 2 (mean change=-1,736 pmol/L (95{\%} CI, -804 to -2,668), P<0.001) but not in groups 1 or 3 (623 pmol/L (-631 to 1877 pmol/L), P=0.14 and 685 pmol/L (-304 to 1068 pmol/L), P=0.46, respectively). Serum BUN and creatinine did not change significantly between visit 0 and visit 2 in group 1 (median=23 mg/dL (range 13-32) vs. 19 mg/dL (12-38), P=0.72 and1.15 mg/dL (0.70 – 1.40) vs. 0.95 mg/dL (0.70 – 1.10), P=0.10, respectively) or group 2 (28 mg/dL (18-87) vs. 43.5 mg/dL (21-160), P=0.092 and 1.10 mg/dL (0.90 – 2.50) vs.1.55 mg/dL (0.90 – 3.30), P=0.062, respectively). Conclusions and clinical importance: Use of this treatment escalation algorithm allows effective targeting of therapy for CHF in dogs against an objective criterion.",
keywords = "Biomarker, Treatment, Canine, Endocardiosis",
author = "Melanie Hezzell and Chloe Block and Danielle Laughlin and Oyama, {Mark A}",
year = "2018",
month = "9",
day = "14",
doi = "10.1111/jvim.15228",
language = "English",
volume = "32",
pages = "1509--1516",
journal = "Journal of Veterinary Internal Medicine",
issn = "0891-6640",
publisher = "Wiley",
number = "5",

}

RIS - suitable for import to EndNote

TY - JOUR

T1 - Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease.

AU - Hezzell, Melanie

AU - Block, Chloe

AU - Laughlin, Danielle

AU - Oyama, Mark A

PY - 2018/9/14

Y1 - 2018/9/14

N2 - Background: Therapy targeted to achieve reduction in N-terminal pro-B-type natriuretic peptide (NT-proBNP) improves outcomes in human congestive heart failure (CHF) patients. Hypothesis: A pre-specified therapeutic algorithm that increased diuretic or pimobendan usage will reduce plasma NT-proBNP concentrations in dogs with CHF secondary to myxomatous mitral valve disease (MMVD). Animals: Twenty-six dogs with clinically stable CHF secondary to MMVD. Methods: Prospective, controlled before-and-after study. Dogs were examined up to 3 times over 21 days. Treatment was prescribed based on NT-proBNP as follows: <1500 pmol/L at baseline, no therapy adjustment at any point during the study (group 1); ≥1500 pmol/L and creatinine ≤3.0 mg/dL at baseline or subsequent visits, therapy escalated according to the algorithm (group 2); ≥1500 pmol/L at baseline, no therapy adjustment (group 3). Results: NT-proBNP decreased significantly in group 2 (mean change=-1,736 pmol/L (95% CI, -804 to -2,668), P<0.001) but not in groups 1 or 3 (623 pmol/L (-631 to 1877 pmol/L), P=0.14 and 685 pmol/L (-304 to 1068 pmol/L), P=0.46, respectively). Serum BUN and creatinine did not change significantly between visit 0 and visit 2 in group 1 (median=23 mg/dL (range 13-32) vs. 19 mg/dL (12-38), P=0.72 and1.15 mg/dL (0.70 – 1.40) vs. 0.95 mg/dL (0.70 – 1.10), P=0.10, respectively) or group 2 (28 mg/dL (18-87) vs. 43.5 mg/dL (21-160), P=0.092 and 1.10 mg/dL (0.90 – 2.50) vs.1.55 mg/dL (0.90 – 3.30), P=0.062, respectively). Conclusions and clinical importance: Use of this treatment escalation algorithm allows effective targeting of therapy for CHF in dogs against an objective criterion.

AB - Background: Therapy targeted to achieve reduction in N-terminal pro-B-type natriuretic peptide (NT-proBNP) improves outcomes in human congestive heart failure (CHF) patients. Hypothesis: A pre-specified therapeutic algorithm that increased diuretic or pimobendan usage will reduce plasma NT-proBNP concentrations in dogs with CHF secondary to myxomatous mitral valve disease (MMVD). Animals: Twenty-six dogs with clinically stable CHF secondary to MMVD. Methods: Prospective, controlled before-and-after study. Dogs were examined up to 3 times over 21 days. Treatment was prescribed based on NT-proBNP as follows: <1500 pmol/L at baseline, no therapy adjustment at any point during the study (group 1); ≥1500 pmol/L and creatinine ≤3.0 mg/dL at baseline or subsequent visits, therapy escalated according to the algorithm (group 2); ≥1500 pmol/L at baseline, no therapy adjustment (group 3). Results: NT-proBNP decreased significantly in group 2 (mean change=-1,736 pmol/L (95% CI, -804 to -2,668), P<0.001) but not in groups 1 or 3 (623 pmol/L (-631 to 1877 pmol/L), P=0.14 and 685 pmol/L (-304 to 1068 pmol/L), P=0.46, respectively). Serum BUN and creatinine did not change significantly between visit 0 and visit 2 in group 1 (median=23 mg/dL (range 13-32) vs. 19 mg/dL (12-38), P=0.72 and1.15 mg/dL (0.70 – 1.40) vs. 0.95 mg/dL (0.70 – 1.10), P=0.10, respectively) or group 2 (28 mg/dL (18-87) vs. 43.5 mg/dL (21-160), P=0.092 and 1.10 mg/dL (0.90 – 2.50) vs.1.55 mg/dL (0.90 – 3.30), P=0.062, respectively). Conclusions and clinical importance: Use of this treatment escalation algorithm allows effective targeting of therapy for CHF in dogs against an objective criterion.

KW - Biomarker

KW - Treatment

KW - Canine

KW - Endocardiosis

U2 - 10.1111/jvim.15228

DO - 10.1111/jvim.15228

M3 - Article

VL - 32

SP - 1509

EP - 1516

JO - Journal of Veterinary Internal Medicine

JF - Journal of Veterinary Internal Medicine

SN - 0891-6640

IS - 5

ER -